Convergence of direct and indirect pharmacodynamic response models.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

28 citing papers in PubMed.

1. Modelling the anti-migraine effects of BIBN 4096 BS: a new calcitonin gene-related peptide receptor antagonist.Clinical pharmacokinetics · 2006
   Trial
2. The time of maximum effect for model selection in pharmacokinetic-pharmacodynamic analysis applied to frusemide.British journal of clinical pharmacology · 1998
   Trial
3. Computational analysis of 5-fluorouracil anti-tumor activity in colon cancer using a mechanistic pharmacokinetic/pharmacodynamic model.PLoS computational biology · 2022
   Article
4. Transitioning from Basic toward Systems Pharmacodynamic Models: Lessons from Corticosteroids.Pharmacological reviews · 2020
   Review
5. Modelling the delay between pharmacokinetics and EEG effects of morphine in rats: binding kinetic versus effect compartment models.Journal of pharmacokinetics and pharmacodynamics · 2018
   Article
6. Translational Modeling to Guide Study Design and Dose Choice in Obesity Exemplified by AZD1979, a Melanin-concentrating Hormone Receptor 1 Antagonist.CPT: pharmacometrics & systems pharmacology · 2017
   Article
7. Bringing Model-Based Prediction to Oncology Clinical Practice: A Review of Pharmacometrics Principles and Applications.The oncologist · 2016
   Review
8. Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates.PloS one · 2016
   Observational
9. Modeling energy intake by adding homeostatic feedback and drug intervention.Journal of pharmacokinetics and pharmacodynamics · 2015
   Article
10. Pharmacologic considerations in use and development of antituberculosis drugs.Cold Spring Harbor perspectives in medicine · 2014
    Review
11. A population pharmacodynamic model for lactate dehydrogenase and neuron specific enolase to predict tumor progression in small cell lung cancer patients.The AAPS journal · 2014
    Article
12. Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2014
    Article
13. A modeling approach for compounds affecting body composition.Journal of pharmacokinetics and pharmacodynamics · 2013
    Article
14. Stochastic modeling of systems mapping in pharmacogenomics.Advanced drug delivery reviews · 2013
    Article
15. Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib.The AAPS journal · 2013
    Article
16. Mechanism-based pharmacodynamic modeling.Methods in molecular biology (Clifton, N.J.) · 2012
    Article
17. Comparative performance of cell life span and cell transit models for describing erythropoietic drug effects.The AAPS journal · 2011
    Article
18. Collapsing mechanistic models: an application to dose selection for proof of concept of a selective irreversible antagonist.Journal of pharmacokinetics and pharmacodynamics · 2005
    Article
19. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.Clinical pharmacokinetics · 2005
    Review
20. Application of a combined "effect compartment/indirect response model" to the central nervous system effects of tiagabine in the rat.Journal of pharmacokinetics and biopharmaceutics · 1999
    Article

Corrections and comments

• Comment on
  A general conceptual model for non-steady state pharmacokinetic/pharmacodynamic data.1995

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as